Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

被引:2
|
作者
Vonk, Steffie E. M. [1 ]
Altenburg, Josje [2 ]
Mathot, Ron A. A. [1 ]
Kemper, E. Marleen [1 ,3 ]
机构
[1] Univ Amsterdam, Dept Hosp Pharm & Clin Pharmacol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Dept Pulm Med, Amsterdam UMC, Meibergdreef 9, Amsterdam, Netherlands
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC, Amsterdam, Netherlands
关键词
Elexacaftor-tezacaftor-ivacaftor; Therapeutic drug monitoring; Area under the curve; Trough concentration; CFTR modulators;
D O I
10.1016/j.jcf.2024.03.010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Therapeutic drug monitoring (TDM) of elexacaftor, tezacaftor, ivacaftor (ETI) could be a useful tool to increase efficacy and decrease the risk of adverse effects in people with Cystic Fibrosis (pwCF). It is however unclear whether drug exposure should be monitored by assessment of trough (C-min) levels or determination of the area under the curve (AUC). Hence, in this study the correlation between measured C min concentration and AUC was evaluated. Serial plasma samples, including C-min , were drawn after administration of ETI in order to calculate the AUC and assess the correlation between the two parameters. A linear correlation between C- min and AUC 0-24h was found, with Pearson's r correlation coefficients of 0.963, 0.908 and 0.860 for elexacaftor, tezacaftor and ivacaftor, respectively. Exposure of ETI may be monitored by assessment of C( min )levels.
引用
收藏
页码:1007 / 1009
页数:3
相关论文
共 50 条
  • [41] Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis
    Cavinato, Luca
    Luly, Francesco R.
    Pastore, Valentina
    Chiappetta, Daniele
    Sangiorgi, Gloria
    Ferrara, Eva
    Baiocchi, Pia
    Mandarello, Giuseppe
    Cimino, Giuseppe
    Del Porto, Paola
    Ascenzioni, Fiorentina
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (04)
  • [42] Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor
    Lowry, Sarah
    Mogayzel, Peter J.
    Oshima, Kiyoko
    Karnsakul, Wikrom
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (02) : E99 - E101
  • [43] Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease
    Djavid, Amir Reza
    Thompson, Alison E.
    Irace, Alexandria L.
    Gusman, Elen
    Altman, Kimberly
    DiMango, Emily A.
    Keating, Claire L.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (11) : 1924 - 1927
  • [44] Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis
    Lyman, Benjamin C.
    Seay, Jessica
    Contreary, Casey
    Savant, Adrienne P.
    Dell, Mary Lynn
    Hescock, George C.
    PEDIATRIC PULMONOLOGY, 2022, 57 (12) : 3174 - 3176
  • [45] Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor
    Meltzer, Lisa J.
    Gross, Jane E.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (01) : 132 - 136
  • [46] IMPACT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON TACROLIMUS TROUGH LEVELS IN INDIVIDUALS AT LEAST 3 YEARS POST-LUNG TRANSPLANT
    Turowski, J. B.
    Lehr, C. J.
    Valapour, M.
    Dasenbrook, E.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S349 - S349
  • [47] A Trifecta for Anxiety: A Case Report of Elexacaftor/Tezacaftor/Ivacaftor Associated Anxiety
    Corona, Benjamin
    Fukui, Miyuki
    Fu, Bo
    JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY, 2023, 64 : S98 - S98
  • [48] Elexacaftor/Tezacaftor/Ivacaftor (ETI) in Combination With Tacrolimus After Lung Transplant
    Guimbellot, J. S.
    Acosta, E. P.
    Ryan, K. J.
    Chalamalla, A.
    Baker, E.
    Bartlett, L.
    Bergeron, J.
    Turner, G.
    Ramos, K. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [49] Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor
    Mingora, Christina M.
    Caverly, Lindsay J.
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (01) : 3 - 4
  • [50] The impact of elexacaftor/tezacaftor/ivacaftor on adherence to maintenance therapies in cystic fibrosis
    Johnson, Ellie
    Land, Rachel
    Reid, David
    RESPIROLOGY, 2024, 29 : 7 - 7